A Phase 3, Open-label Study Evaluating the Longterm Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Project Details

StatusActive
Effective start/end date24/08/22 → 30/06/25

Funding

  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$10,000.00
  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$5,000.00
  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$25,000.00
  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$5,000.00
View all
View less